110 related articles for article (PubMed ID: 30798084)
1. Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS).
Adenis A; Bennouna J; Etienne PL; Bogart E; Francois E; Galais MP; Ben Abdelghani M; Michel P; Metges JP; Dahan L; Conroy T; Ghiringhelli F; Drouillard A; El Hajbi F; Samalin E; Hiret S; Delaine-Clisant S; Mariette C; Penel N; Piessen G; Le Deley MC
Eur J Cancer; 2019 Apr; 111():12-20. PubMed ID: 30798084
[TBL] [Abstract][Full Text] [Related]
2. Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial.
Marguet S; Adenis A; Delaine-Clisant S; Penel N; Bonastre J
Value Health; 2021 May; 24(5):676-682. PubMed ID: 33933236
[TBL] [Abstract][Full Text] [Related]
3. Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
Adenis A; Kulkarni AS; Girotto GC; de la Fouchardiere C; Senellart H; van Laarhoven HWM; Mansoor W; Al-Rajabi R; Norquist J; Amonkar M; Suryawanshi S; Bhagia P; Metges JP
J Clin Oncol; 2022 Feb; 40(4):382-391. PubMed ID: 34730989
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
Bascoul-Mollevi C; Gourgou S; Galais MP; Raoul JL; Bouché O; Douillard JY; Adenis A; Etienne PL; Juzyna B; Bedenne L; Conroy T
Eur J Cancer; 2017 Oct; 84():239-249. PubMed ID: 28829992
[TBL] [Abstract][Full Text] [Related]
5. Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.
Randrian V; Adenis A; Desrame J; Barbier E; Di Fiore F; Lièvre A; Dahan L; Laurent-Puig P; Mineur L; Breysacher G; Roquin G; Louafi S; Lopez A; Louvet C; Borg C; Metges JP; Faroux R; Gaba L; Manfredi S; Tougeron D
Dig Liver Dis; 2020 Mar; 52(3):347-350. PubMed ID: 31899122
[TBL] [Abstract][Full Text] [Related]
6. Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study.
Ajani J; El Hajbi F; Cunningham D; Alsina M; Thuss-Patience P; Scagliotti GV; Van den Eynde M; Kim SB; Kato K; Shen L; Li L; Ding N; Shi J; Barnes G; Van Cutsem E
ESMO Open; 2024 Jan; 9(1):102202. PubMed ID: 38118368
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
Lee SJ; Kim S; Kim M; Lee J; Park YH; Im YH; Park SH
BMC Cancer; 2015 Oct; 15():693. PubMed ID: 26468007
[TBL] [Abstract][Full Text] [Related]
8. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
10. Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life.
Van Cutsem E; Kato K; Ajani J; Shen L; Xia T; Ding N; Zhan L; Barnes G; Kim SB
ESMO Open; 2022 Aug; 7(4):100517. PubMed ID: 35785595
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Huang J; Xu B; Liu Y; Huang J; Lu P; Ba Y; Wu L; Bai Y; Zhang S; Feng J; Cheng Y; Li J; Wen L; Yuan X; Ma C; Hu C; Fan Q; Wang X
Cancer Commun (Lond); 2019 Apr; 39(1):16. PubMed ID: 30940189
[TBL] [Abstract][Full Text] [Related]
12. Is chemotherapy for advanced or metastatic oesophageal squamous cell carcinoma no longer needed?
van Laarhoven HW
Lancet Oncol; 2020 Jun; 21(6):743-745. PubMed ID: 32502437
[No Abstract] [Full Text] [Related]
13. Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma.
Sun S; Yu H; Wang H; Zhang H; Wu X; Wang J; Chang J
Oncol Res Treat; 2019; 42(3):115-122. PubMed ID: 30799403
[TBL] [Abstract][Full Text] [Related]
14. Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2).
Ai D; Chen Y; Liu Q; Zhang J; Deng J; Zhu H; Ren W; Zheng X; Li Y; Wei S; Ye J; Zhou J; Lin Q; Luo H; Cao J; Li J; Huang G; Wu K; Fan M; Yang H; Zhu Z; Zhao W; Li L; Fan J; Badakhshi H; Zhao K
BMJ Open; 2018 Oct; 8(10):e020785. PubMed ID: 30344165
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
16. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival.
Conroy T; Etienne PL; Adenis A; Ducreux M; Paillot B; Oliveira J; Seitz JF; Francois E; Van Cutsem E; Wagener DJ; Kohser F; Daamen S; Praet M; Gorlia T; Baron B; Wils J;
Ann Oncol; 2002 May; 13(5):721-9. PubMed ID: 12075740
[TBL] [Abstract][Full Text] [Related]
17. A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial.
de Castro Junior G; Segalla JG; de Azevedo SJ; Andrade CJ; Grabarz D; de Araújo Lima França B; Del Giglio A; Lazaretti NS; Álvares MN; Pedrini JL; Kussumoto C; de Matos Neto JN; Forones NM; Fernandes Júnior HJ; Borges G; Girotto G; da Silva IDCG; Maluf-Filho F; Skare NG
Eur J Cancer; 2018 Jan; 88():21-30. PubMed ID: 29179134
[TBL] [Abstract][Full Text] [Related]
18. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
[TBL] [Abstract][Full Text] [Related]
20. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
